264 studies found for:    CLL [CONDITION] | Open Studies
Show Display Options
Rank Status Study
1 Unknown  Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   CLL;   Untreated;   Front-line;   First-Line;   Initial Therapy
Intervention: Drug: Lenalidomide and Rituximab
2 Recruiting Natural Killer Cells and Bortezomib to Treat Cancer
Conditions: Lung or Prostatic Neoplasms;   Colorectal or Kidney Neoplasms;   Pancreatic Neoplasms;   Leukemia, Myelogenous, Chronic Lymphocytic Leukemia, BCR-ABL Positive;   Melanoma;   CLL
Intervention: Drug: NK cells +CliniMACs CD3 and CD56 systems
3 Recruiting Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients
Conditions: CLL;   B-cell;   Small Lymphocytic Lymphoma;   Untreated B-CLL;   Elderly Patients
Intervention:
4 Recruiting Registry of the German CLL Study Group
Conditions: CLL;   SLL;   HCL;   Richter´s Transformation;   Leukemia, Prolymphocytic, B-Cell;   Leukemia, Prolymphocytic, T-Cell;   T-LGL Leukemia;   NK-LGL Leukemia
Intervention:
5 Recruiting Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in 17p- Chronic Lymphocytic Leukemia (CLL)
Condition: CLL
Intervention:
6 Recruiting Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
Conditions: CLL;   SLL
Interventions: Drug: Ofatumumab;   Drug: High-Dose Methylprednisolone;   Drug: Alemtuzumab
7 Recruiting informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention:
8 Recruiting Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL
Conditions: Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma
Interventions: Biological: MOR00208;   Drug: lenalidomide;   Other: Correlative Studies
9 Recruiting Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
Conditions: Chronic Kidney Disease;   Acute Myeloid Leukemia (AML);   Acute Lymphoblastic Leukemia (ALL);   Chronic Myelogenous Leukemia (CML);   Chronic Lymphocytic Leukemia (CLL);   Non-Hodgkin's Lymphoma (NHL);   Hodgkin Disease;   Multiple Myeloma;   Myelodysplastic Syndrome (MDS);   Aplastic Anemia;   AL Amyloidosis;   Diamond Blackfan Anemia;   Myelofibrosis;   Myeloproliferative Disease;   Sickle Cell Anemia;   Autoimmune Diseases;   Thalassemia
Intervention: Procedure: Haploidentical Bone Marrow/Kidney
10 Recruiting Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation
Conditions: Acute Lymphoblastic Leukemia (ALL);   Acute Myelogenous Leukemia (AML);   Chronic Lymphocytic Leukemia (CLL);   Chronic Myelogenous Leukemia (CML);   MDS
Intervention: Device: CliniMACS CD34 selection system
11 Recruiting IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
Conditions: Acute Myelogenous Leukemia (AML);   Acute Lymphoblastic Leukemia (ALL);   Myelodysplastic Syndromes (MDS);   Lymphoma;   Myeloma;   Chronic Lymphocytic Leukemia (CLL);   Chronic Myelogenous Leukemia (CML)
Intervention: Biological: ALT-803
12 Recruiting Cord Blood Transplant
Conditions: Chronic Myelogenous Leukemia (CML);   Acute Myelogenous Leukemia (AML);   Myelodysplastic Syndrome;   Multiple Myeloma;   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia (CLL);   Acute Lymphocytic Leukemia (ALL);   Severe Aplastic Anemia
Intervention: Genetic: umbilical cord transplant (UCB)
13 Not yet recruiting Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Ibrutinib in Patients With Relapsed Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Obinutuzumab;   Drug: Atezolizumab
14 Recruiting Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Venetoclax
15 Recruiting Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL
Conditions: Non-hodgkin's Lymphoma;   Follicular Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: IMMU-114
16 Recruiting Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: dimethyl fumarate
17 Not yet recruiting UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Conditions: Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia/Lymphoma;   Burkitt's Lymphoma;   Natural Killer Cell Malignancies;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Large-cell Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-cell Lymphoma;   Prolymphocytic Leukemia;   Bone Marrow Failure Syndromes;   Myeloproliferative Syndromes
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: MMF;   Drug: Sirolimus;   Radiation: TBI;   Biological: Umbilical cord blood cell infusion;   Biological: ATG
18 Not yet recruiting Allo HSCT Using RIC for Hematological Diseases
Conditions: Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Myeloproliferative Syndromes;   Hematological Diseases
Interventions: Drug: Allopurinol;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: ATG;   Radiation: TBI;   Drug: Tacrolimus;   Drug: MMF;   Biological: Peripheral Blood Stem Cells;   Biological: Related or Unrelated Bone Marrow Cells
19 Not yet recruiting Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib in R/R CLL/SLL Patients Pretreated With BTKi
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Biological: MOR00208;   Drug: idelalisib
20 Recruiting Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: Lenalidomide, Ibrutinib, Rituximab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years